

UNITED STATES PATENT AND TRADEMARK OFFICE

AB

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/518,297	03/03/2000	Moon Young Lim	4600-0130.30 5390			
22918 , 75	22918 7590 11/12/2004			EXAMINER		
PERKINS CO	PERKINS COIE LLP			KAM, CHIH MIN		
	P.O. BOX 2168 MENLO PARK, CA 94026			PAPER NUMBER		
MEN DO TAME	, 0.1 > 1020		1653	*		
			DATE MAILED: 11/12/200	DATE MAILED: 11/12/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicat	on No.	Applicant(s)	
		09/518,2	97	LIM ET AL.	
Office Action Summary		Examine	r	Art Unit	
	1	Chih-Min		1653	
T Period for R	he MAILING DATE of this communicated	ation appears on th	e cover sheet with the c	orrespondence address	
A SHOR THE MA - Extension after SIX - If the peri - If NO peri - Failure to Any reply	TENED STATUTORY PERIOD FOR ILING DATE OF THIS COMMUNIC, is of time may be available under the provisions of (6) MONTHS from the mailing date of this communication reply specified above, the maximum status of for reply specified above, the maximum status reply within the set or extended period for reply will received by the Office later than three months after them term adjustment. See 37 CFR 1.704(b).	ATION. 37 CFR 1.136(a). In no evication. days, a reply within the sta ory period will apply and v I, by statute, cause the app	vent, however, may a reply be tim tutory minimum of thirty (30) days vill expire SIX (6) MONTHS from plication to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).	
Status					
2a)∐ Th 3)⊠ Sir	sponsive to communication(s) filed is action is FINAL . 2b ace this application is in condition fo sed in accordance with the practice)☐ This action is r r allowance excep	non-final. t for formal matters, pro		
Disposition	of Claims				
4a) 5)⊠ Cla 6)□ Cla 7)□ Cla	aim(s) 52,53 and 60-63 is/are pending of the above claim(s) is/are aim(s) 52,53 and 60-63 is/are allowers aim(s) is/are rejected. aim(s) is/are objected to aim(s) are subject to restriction	withdrawn from co	onsideration.		
Application	Papers				
10)∐ The Ap _l Re _l	e specification is objected to by the E drawing(s) filed on is/are: a plicant may not request that any objection placement drawing sheet(s) including the e oath or declaration is objected to be) accepted or b on to the drawing(s) e correction is requi	be held in abeyance. See red if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).	
Priority und	er 35 U.S.C. § 119				
a)	Certified copies of the priority do	cuments have been cuments have been the priority documents laureau (PCT Rules)	en received. en received in Application ents have been receive le 17.2(a)).	on No d in this National Stage	
Attachment(s)					
1) Notice of 2) Notice of 3) Informatio	References Cited (PTO-892) Draftsperson's Patent Drawing Review (PTO In Disclosure Statement(s) (PTO-1449 or PT (s)/Mail Date	-948) O/SB/08)	4) Interview Summary (Paper No(s)/Mail Dai 5) Notice of Informal Pa 6) Other:	te. <u>20041109; 20041007</u> .	

Application/Control Number: 09/518,297

Art Unit: 1653

1. This application is in condition for allowance except for the following formal matters:

This application contains nucleotide sequences (e.g., sequences in Tables 9 and 10) that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequences. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825).

The specification cites "Fig. 9A" at page 9, line 12, however, there is no "Fig. 9A".

The specification cites "IX." at page 37, line 16, which should be "VII.".

The specification cites "X." at page 38, line 7, which should be "VIII.".

The specification cites "XI." at page 40, line 43, which should be "IX.".

The specification cites "XII." at page 45, line 1, which should be "X.".

The specification cites "XIII." at page 52, line 3, which should be "XI.".

The specification cites "IX." at page 52, line 14, which should be "XII.".

Prosecution on the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

A shortened statutory period for reply to this action is set to expire **TWO MONTHS** from the mailing date of this letter.

Application/Control Number: 09/518,297

Art Unit: 1653

Page 3

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached at 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chih-Min Kam, Ph. D. Cryk
Patent Examiner

CMK November 9, 2004

JON WEBEH
SUPERVISORY PATENT EXAMINER

Application No. Applicant(s) 09/518,297 Lim et al. **Notice to Comply** Examiner Art Unit C.M. Kam 1653

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under

the provisions of 37 CFR 1.136(a)).
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
∑ 7. Other: nucleotide sequences cited in the specification (e.g., Tables 9 and 10), however, the sequence identifier "SEQ ID NO:" is not indicated in the sequence listing.
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry nto the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
or questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (571) 272-2510 For CRF Submission Help, call (571) 272-2501/2583. PatentIn Software Program Support Technical Assistance
PLEASE RETURN A CORY OF THIS NOTICE WITH YOUR REDUX